论文部分内容阅读
目的探讨埃克替尼治疗晚期非小细胞肺癌的临床疗效。方法回顾性分析21例晚期非小细胞肺癌患者的临床资料,全部患者均给予口服埃克替尼进行治疗,观察临床疗效。结果本组无完全缓解(CR)患者,部分缓解(PR)10例,占47.6%,疾病稳定(SD)7例,占33.3%,疾病进展(PD)4例,占19.0%,整体疾病控制率(DCR)为81.0%。全部患者平均无进展生存期(PFS)为(8.2±1.5)个月。患者应用埃克替尼治疗的主要毒副反应为皮疹及腹泻。其中,7例患者发生皮疹,皮疹发生率为33.3%。5例患者发生腹泻,腹泻发生率23.8%。3例发生Ⅲ~Ⅳ度毒副反应,总发生率为14.3%,其中2例为Ⅲ度皮疹,1例Ⅲ度腹泻,无Ⅳ度不良反应。结论采用埃克替尼治疗非小细胞肺癌,其疗效确切,毒副反应低,可在临床推广应用。
Objective To investigate the clinical efficacy of icotinib in the treatment of advanced non-small cell lung cancer. Methods The clinical data of 21 patients with advanced non-small cell lung cancer were retrospectively analyzed. All patients were treated with imatinib orally, and the clinical efficacy was observed. Results There were 10 cases (47.6%) with partial remission (PR), 7 cases with stable disease (SD), 33.3% with disease progression (PD), 4 cases with disease progression (PD), 19.0% with overall disease control The rate (DCR) is 81.0%. The mean progression-free survival (PFS) of all patients was (8.2 ± 1.5) months. The main side effects of imatinib therapy in patients are rash and diarrhea. Among them, rash occurred in 7 patients and the incidence of rash was 33.3%. 5 cases of diarrhea, the incidence of diarrhea 23.8%. Three cases had grade Ⅲ ~ Ⅳ toxicities, with a total incidence of 14.3%. Of them, 2 had grade Ⅲ rash, 1 case had grade Ⅲ diarrhea, and no grade Ⅳ adverse reaction. Conclusion Icitinib treatment of non-small cell lung cancer, the curative effect is exact, low toxicity, can be widely used in clinical practice.